Scancell expands its R&D capabilities with new facilities at The Oxford Science Park Oxford, UK, 19 October 2021 – Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for…
Read More
LANDMARK PAPER HIGHLIGHTS EVOX THERAPEUTICS’ CUTTING EDGE EXOSOME ENGINEERING APPROACH FOR ENHANCED SURFACE DISPLAY OF BIOLOGICS Evox’s engineered exosomes show better efficacy compared to conventional biologics and significantly outperformed other…
Magdalen College & GIC enter Strategic Partnership to accelerate development of The Oxford Science Park Investment initiates transformational construction programme as demand for life sciences & technology space continues…
Vatic announces manufacturing partnership with Abingdon Health Abingdon Health plc (“Abingdon Health”), a leading international developer and manufacturer of high quality and effective rapid tests, and Vatic Health Limited (“Vatic”),…
OXFORD, England–(BUSINESS WIRE)– Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the…
Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions is pleased to announce its PARTNER study has recruited…
DR. CAROLIN BARTH JOINS MIROBIO AS CEO TO LEAD PRECISION IMMUNOLOGY COMPANY FOCUSED ON CHECKPOINT AGONIST ANTIBODIES Former Novartis executive to lead emerging biotech with a novel precision approach to…
Exscientia enters $70M collaboration to develop anti-viral therapeutics against Coronavirus and other viruses with pandemic potential Four-year agreement with Bill & Melinda Gates Foundation to discover and develop small molecule…
Regulatory approval of OVM-200 for Phase 1 signals a significant step for Oxford Vacmedix with the first clinical trial of a cancer vaccine based on the recombinant overlapping peptide platform…
Significant expansion of AI firm Exscientia’s headquarters at TOSP Job creation to continue beyond 100 roles added already this year Oxford, UK, August 4 2021 – Exscientia, the clinical stage,…
Dr. David Ruau joins Sensyne Health from Bayer Pharmaceuticals Oxford, U.K. 22 July 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the ethical AI company, today announces the appointment…
Oxford, UK – July 20, 2021 – Orbit Discovery Ltd., (“Orbit”), a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, today…
T-Cypher Bio announces the appointment of Thomas Lars Andresen as Chief Executive Officer Company to be led by award winning, cell therapy expert as it aims to unlock an expansive…
Etcembly establishes new lab & office space at TOSP Immune-focused machine learning firm joins leading AI cohort on Park Oxford, UK, July 8 2021 – Etcembly Ltd, a machine learning…
Nature Biotechnology publishes ATDBio & University of Oxford single-cell sequencing research Better understanding of disease possible with accurate full length identification of all messenger RNA in a cell Oxford, UK,…